Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergence.
Thursday March 18, 2021
9am PT/12pm ET
Speaker: Dr. John McCafferty, IONTAS
In this webinar, Dr. John McCafferty presents results from the deep-mining of the antibody repertoires of hospitalized COVID-19 patients using a combination of phage display technology and B cell receptor repertoire sequencing to isolate neutralizing antibodies and gain insights into the early antibody response. This comprehensive discovery approach yielded potent neutralizing antibodies with distinct mechanisms of action. In particular, a novel non-ACE2 receptor blocking antibody that is not expected to be affected by any of the major viral variants reported was identified. Potent neutralizing antibodies with near germline sequences within both the IgG and IgM pools at early stages of infection were also found. The study results highlight a highly convergent antibody response with the same sequences occurring both within this patient group and within the responses described in previously published anti-SARS-CoV-2 antibody studies.
On Demand Webinars
Broadcast date: February 18, 2021
The SARS-CoV-2 pandemic has spread all over the world in the past year and there is still no efficient treatment available for COVID-19, particularly for patients undergoing severe courses, which often lead to fatal consequences. Antiviral drugs such as virus-neutralizing antibody therapeutics are still urgently needed to save millions of lives.
Corat Therapeutics developed a novel SARS-CoV-2 neutralizing, fully human antibody derived from convalescent patients. Ultra-fast development strategies shortened timelines from discovery to GMP manufactured material to less than 8 months. This was possible by parallelizing discovery and development steps, as well as performing crucial steps on risk. First-in-human studies were recently initiated. This webinar gives an overview of the challenges faced during discovery and development of the lead antibody, COR-101.
Broadcast date: January 21, 2021
The Specifica Generation 3 platform is able to generate 500-5000 different antibody clonotypes against targets of interest, with over 80% of selected antibodies having no measurable biophysical liabilities and 20% having subnanomolar affinities. The most common approach to selecting antibodies from display technologies involves low-throughput random colony screening. However, this misses many potential therapeutic leads, particularly when diversity is high. Specifica uses next generation sequencing (NGS) to build its libraries as well as characterize selection outputs. In order to fully exploit the universe of selectable antibodies, Specifica has developed a cloud-based software platform, designed exclusively for antibody engineers and bioinformaticians, to enable a streamlined identification of leads with broad epitope coverage. Application of this to selection outputs has increased the number of clonotype leads by five to ten fold over random colony screening, significantly expanding the explorable paratope space.